Anales de la RANM

171 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TIPO DE INSULINA BASAL Y RIESGO DE CETOACIDOSIS DIABÉTICA Sebastian-Valles F, et al. An RANM. 2025;142(02): 163 - 171 14. Glaser N, Fritsch M, Priyambada L, et al. IS- PAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglyce- mic hyperosmolar state. Pediatr Diabetes. 2022;23(7):835–856. doi:10.1111/pedi.13406 15. Moran A, Pillay K, Becker D, et al. ISPAD Clini- cal Practice Consensus Guidelines 2018: Manage- ment of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):64–74. doi:10.1111/pedi.12732 16. Johnson SR, Cooper MN, Jones TW, Davis EA (2013) Long-term outcome of insulin pump therapy in children with type 1 diabetes as- sessed in a large population-based case–con- trol study. Diabetologia 56(11):2392–2400. https://doi.org/10.1007/s00125-013-3007-9 17. Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT- 2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666. doi:10.1136/bmj- drc-2023-003666 18. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 inhibitor–associated ketoacido- sis vs type 1 diabetes–associated ketoacido- sis. JAMA Netw Open. 2024;7(3):e242744. doi:10.1001/jamanetworkopen.2024.2744 19. Mahase E. Type 1 diabetes drug was with- drawn because of a "commercial conflict of interest," charity argues. BMJ. 2022;376:o373. doi:10.1136/bmj.o373 20. Takahashi K, Uenishi N, Sanui M, et al. Cli- nical profile of patients with diabetic ketoaci- dosis and hyperglycemic hyperosmolar syn- drome in Japan: A multicenter retrospective cohort study. Acta Diabetol. 2024;61(1):117– 126. doi:10.1007/s00592-023-02181-1 21. Eledrisi MS, Alkabbani H, Aboawon M, et al. Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacido- sis. Diabetes Res Clin Pract. 2022;192:110041. doi:10.1016/j.diabres.2022.11004 22. Johnson SR, Cooper MN, Jones TW, Davis EA (2013) Long-term outcome of insulin pump therapy in children with type 1 diabetes as- sessed in a large population-based case–con- trol study. Diabetologia 56(11):2392–2400. https://doi.org/10.1007/s00125-013-3007-9 23. Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT- 2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666. doi:10.1136/bmj- drc-2023-003666 24. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 inhibitor–associated ketoacido- sis vs type 1 diabetes–associated ketoacido- sis. JAMA Netw Open. 2024;7(3):e242744. doi:10.1001/jamanetworkopen.2024.2744 25. Mahase E. Type 1 diabetes drug was with- drawn because of a "commercial conflict of interest," charity argues. BMJ. 2022;376:o373. doi:10.1136/bmj.o373 26. Takahashi K, Uenishi N, Sanui M, et al. Cli- nical profile of patients with diabetic ketoaci- dosis and hyperglycemic hyperosmolar syn- drome in Japan: A multicenter retrospective cohort study. Acta Diabetol. 2024;61(1):117– 126. doi:10.1007/s00592-023-02181-1 27. Eledrisi MS, Alkabbani H, Aboawon M, et al. Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacido- sis. Diabetes Res Clin Pract. 2022;192:110041. doi:10.1016/j.diabres.2022.11004 Si desea citar nuestro artículo: Marazuela M, Navas-Moreno V, Sager-La Ganga C, Tapia-San- chiz MS, Lopez-Ruano M, Martinez-Otero C, Carrillo-López E, Raposo-López JJ, Amar S, González Castañar S, Arranz- Martin JA, Sebastian-Valles F. Tipo de insulina basal y ries- go de cetoacidosis diabética en personas con diabetes tipo 1: un estudio de casos y controles. An RANM. 2025;142(02): 163– 171. DOI: 10.32440/ar.2025.142.02. org01